ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP98-19 Changes to Blue Cross Mailing Addresses
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 27, 2019
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2611 - 2620 လၢ 3273 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2019 December Provider Press
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 21, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP40R1-19 Medical Drug Update for Drug Golodirsen (Vyondys 53)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP40-19 Medical Drug Update for New to Market Golodirsen (Vyondys 53)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP86-19 Pharmacy Benefit Exclusion for Invermectin Cream 1%
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP90-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: tadalafil
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP89-19 CMS Provider Data Accuracy Audit
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP88-19 Pharmacy Benefit Exclusion for Healthcare Professional Administered Drugs
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP87-19 Medical Drug Exclusion Lists Expanded to Include Triluron – Commercial Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP92-19 Multiple Claim Appeals for Minnesota Health Care Programs (MHCP)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2019